Preview: Life Sciences IP Summit 2016

C5’s Life Sciences IP Summit returns for its third year, offering a comprehensive programme that is bursting with variety, topical relevance and focused discussion on the issues that really matter.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility

20 October 2026 In closing arguments last week, the drugmaker urged the UK Patents Court to reject an overly critical approach to plausibility and consider what its patents disclose when read as a whole rather than individually.

Pharma

Boehringer and Dr Reddy’s spar over plausibility as trial wraps up

15 October 2026 A dispute over missing experimental data and patent disclosures draws to a close as Boehringer and Dr Reddy’s deliver their final arguments. The court’s decision could bring greater clarity to the UK approach to plausibility and determine whether Dr Reddy’s can move ahead with its proposed generic launch.

Pharma

Accord’s generic hopes dashed in cyanide antidote ruling

14 October 2026 Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.

More features

WATCH: Medmix global IP head on building business-focused IP teams

Fed Circ refuses to rehear Insulet’s $59.4m trade secret loss

Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility

Align Technology notches another win in escalating clear aligner feud

Guardant loses second patent challenge to TwinStrand amid $245m damages fallout

Boehringer and Dr Reddy’s spar over plausibility as trial wraps up

Haynes Boone expands in California with new office

Accord’s generic hopes dashed in cyanide antidote ruling

Preview: Life Sciences IP Summit 2016

More on this story

Editor's picks

Editor's picks

More features